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INTRODUCTION 
 
Rheumatoid arthritis (RA) is a chronic crippling disease that affects various organ 
systems including the kidney. RA is the second most common rheumatologic problem next only 
to Systemic lupus erythematosus. Renal involvement in RA can be either due to the disease per 
se or due to the drugs used to treat the condition. RA can affect all the components of the kidney 
including the glomerulus, tubules, interstitium and the blood vessels. Most of the patients will be 
taking non-steroidal anti-inflammatory drugs, the potential renal toxicity of which is well known. 
Gold and penicillamine used in the management of RA has been very well known for their 
nephrotoxic potential by causing secondary membranous nephropathy. Some patients 
particularly those residing in the rural areas of Indian sub-continent might take indigenous 
medicines for the treatment of RA. If these indigenous medicines contain nephrotoxic 
substances, it adds up to the renal injury. Presence of other comorbidities like hypertension and 
atherosclerosis also affects the course and prognosis of renal disease in rheumatoid arthritis. 
Renal disease in RA is usually asymptomatic and detected only in laboratory 
investigations. Urine analysis for microalbuminuria, proteinuria, red blood cells and red blood 
cell cast and blood biochemistry including urea, creatinine and electrolytes still remains as the 
cost effective tool for screening renal disease in RA. However renal biopsy remains the ‘gold 
standard’ investigation for the diagnosis of renal pathology with certainty. Great emphasis has to 
be placed on regular and periodic screening, because the detection of renal disease early has got 
two implications. First, most of the drug induced renal lesions resolve spontaneously after 
prompt cessation of the offending drug; say for an example gold induced membranous 
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nephropathy. Second, some of the disease modifying anti-rheumatic drugs require dose reduction 
in the presence of renal failure like methotrexate.    
There are various clinical case series and autopsy studies available in the literature 
highlighting the renal involvement in RA. Most of the studies come either from Japan or from 
other overseas countries. Except for few case reports, there are not much of Indian studies 
regarding the renal involvement in RA. This study is intended to evaluate renal lesion in RA 
among Indian patients in a tertiary care hospital in south India. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 
 
 
 
 
AIM OF THE STUDY 
 
 
 
 
 
¾ To evaluate renal lesions in patients with Rheumatoid arthritis and to assess 
the clinicopathologic correlations. 
 
¾ To assess the course and prognosis of renal diseases in patients with 
Rheumatoid arthritis. 
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REVIEW OF LITERATURE 
 
 INTRODUCTION 
Rheumatoid arthritis (RA) is a chronic systemic disease of unknown cause. The 
characteristic feature of established RA is persistent inflammatory synovitis, usually involving 
peripheral joints in a symmetric distribution. The hallmark of the disease is cartilage damage and 
bone erosions secondary to the synovial inflammation. The course of RA can be quite variable. 
The disease severity can vary from mild oligoarticular involvement with minimal joint damage 
to a widespread progressive polyarthritis resulting in marked functional impairment. 
EPIDEMIOLOGY AND GENETICS 
Rheumatoid arthritis affects about 1% of the population1, in a female/male ratio of 2·5/1. 
The prevalence increases with age, and sex differences diminish in the older age group. Onset of 
the disease is most frequent during the fourth and fifth decades of life, with 80% of all patients 
developing the disease between the ages of 35 and 50. RA is seen throughout the world and 
affects all races. However, the incidence and severity seem to be less in rural sub-Saharan Africa 
and in Caribbean blacks. 
Family studies indicate a genetic predisposition. Severe RA is found at approximately 
four times the expected rate in first-degree relatives. The concordance rate of RA in monozygotic 
twins varies from 12 to 15%, implying that factors other than genetics play an important 
etiopathogenic role2,3. The major genetic risk factors for RA are located in major 
histocompatibility complex (MHC) with allelic variation in the HLA-DRB1 gene, which encodes 
the MHC II beta-chain molecule. Additional genes in the HLA-D complex may also convey 
susceptibility to RA. 
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Environmental factors also play a role in the etiology of the disease. Epidemiologic 
studies in Africa have indicated that climate and urbanization have a major impact on the 
incidence and severity of RA. Smoking is also an important risk for RA in persons expressing an 
HLA-beta 1 susceptibility allele. 
Various infectious agents has been suggested including Mycoplasma, Epstein-Barr virus 
(EBV), cytomegalovirus, parvovirus, and rubella virus, but convincing evidence regarding their 
causative role has not emerged.  
PATHOGENESIS 
The pathogenic mechanisms of synovial inflammation are likely to result from a complex 
interplay of genetic, environmental, and immunologic factors that produces dysregulation of the 
immune system (Fig.1). Precisely what triggers these initiating events and what genetic and 
environmental factors disrupt the immune system remain a mystery. The earliest pathogenic 
mechanism identified in RA is breakdown in self-tolerance. This is supported by the finding that 
autoantibodies, such as rheumatoid factor(RF) and antibodies to cyclic citrullinated peptides 
(anti-CCPs) may be found in sera from patients long before clinical disease. The pathogenesis of 
RA is built upon the concept that self-reactive T cells drive the chronic inflammatory response. 
In the rheumatoid joint, by mechanisms of cell-cell contact and release of soluble mediators, 
activated T cells stimulate macrophages and fibroblast-like synoviocytes to generate 
proinflammatory mediators and proteases that drive the synovial inflammatory response and 
destroy the cartilage and bone. CD4+ T cells also provide help to B cells, which in turn, produce 
antibodies that may promote further inflammation in the joint. RFs may form large immune 
complexes inside the joint that contribute to the pathogenic process by fixing complement and 
promoting the release of proinflammatory chemokines and chemoattractants. 
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Fig-1: Genetic and environmental factors cause a break in self tolerance and activate auto-
reactive T cells that release inflammatory cytokines which in turn stimulate osteoclasts resulting 
in bone and joint destruction4. 
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PATHOLOGY 
Rheumatoid arthritis affects the synovial tissue and underlying cartilage and bone. The 
synovial membrane covers most articular surfaces, tendon sheaths, and bursae. The pathologic 
hallmarks of RA are synovial inflammation and proliferation, focal bone erosions, and thinning 
of articular cartilage. The structural damage to the mineralized cartilage and subchondral bone is 
mediated by the osteoclast. Chronic inflammation leads to synovial lining hyperplasia and the 
formation of pannus, a thickened cellular membrane of granulation–reactive fibrovascular tissue 
that invades the underlying cartilage and bone5.  
CLINICAL FEATURES 
Patients often complain of early morning joint stiffness lasting more than 1 hour and 
easing with physical activity. The earliest involved joints are typically the small joints of the 
hands and feet. The initial pattern of joint involvement may be monoarticular, oligoarticular (<4 
joints), or polyarticular (>5 joints), usually in a symmetric distribution. Some patients with an 
inflammatory arthritis will present with too few affected joints and other characteristic features 
to be classified as having RA—so-called undifferentiated inflammatory arthritis. 
Once the disease process of RA is established, the wrists, metacarpophalangeal (MCP), 
and proximal interphalangeal (PIP) are the most frequently involved joints. Flexor tendon 
tenosynovitis is a frequent hallmark of RA. Ulnar deviation results from subluxation of the MCP 
joints and proximal phalanx. Hyperextension of the PIP joint with flexion of the DIP joint 
("swan-neck deformity"), flexion of the PIP joint with hyperextension of the DIP joint 
("boutonnière deformity"), and subluxation of the first MCP joint with hyperextension of the first 
interphalangeal (IP) joint ("Z-line deformity") also may result from damage to the tendons, joint 
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capsule, and other soft tissues in these small joints. Atlantoaxial-subluxation is clinically 
noteworthy because of its potential to cause compressive myelopathy. 
EXTRAARTICULAR MANIFESTATIONS 
Extraarticular manifestations may develop at any time during the clinical course of RA, 
sometimes even prior to the onset of arthritis. Constitutional symptoms include weight loss, 
fever, fatigue, malaise and depression.  
ORGAN SYSTEM INVOLVEMENT 
Skin Rheumatoid nodules, vasculitis 
Ocular Keratoconjunctivitis sicca, iritis, 
Episcleritis 
Oral Salivary inflammation (sicca symptoms) 
Respiratory Pulmonary fibrosis, pleural 
effusion, cricoarytenoid inflammation 
Cardiac Pericardial inflammation, valvular nodule 
formation, myocarditis 
Renal  Proliferative glomerulonephritis, 
membranous nephropathy, amyloidosis 
Neurological Mononeuritis, nerve entrapment, cervical 
Instability 
Hepatic Increased aminotransferase concentrations 
Haematological Anaemia, thrombocytosis, leucocytosis, 
lymphadenopathy 
Felty’s syndrome: splenomegaly, 
Thrombocytopenia 
Vascular Vasculitis 
 
Table-1: Extraarticular manifestations in Rheumatoid Arthritis 
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LABORATORY FINDINGS 
Like any other autoimmune disease, there is no specific test to diagnose RA with 
certainty.  Rheumatoid factors (RF) are autoantibodies reactive against the Fc portion of IgG. 
These autoantibodies are usually of IgM in nature.  Rheumatoid factors are usually detected in 
more than two-thirds of adults and have been used to evaluate patients with RA. However, RF is 
not specific for RA as it is found in 5% of normal adults.  The prevalence of RF increases with 
age and has been found in 10 to 20% of individuals more than 65 years of age. Other disease 
conditions associated with positive RF includes systemic lupus erythematosus, Sjögren's 
syndrome, interstitial pulmonary fibrosis, sarcoidosis, hepatitis B, chronic liver disease, 
infectious mononucleosis, tuberculosis, leprosy, syphilis, subacute bacterial endocarditis, 
visceral leishmaniasis, schistosomiasis and malaria. It may also appear transiently in normal 
individuals after vaccination or transfusion. The presence of rheumatoid factor does not establish 
the diagnosis of RA. However, the presence of RF can be of prognostic significance because 
patients with high titers tend to have more severe and progressive disease with extraarticular 
manifestations. RF is uniformly found in patients with nodules or vasculitis. 
Other serologic test used to evaluate patients with RA is antibodies to cyclic citrullinated 
peptides (anti-CCP). These antibodies are usually found in rheumatoid factor–positive patients, 
on occasion they can be detected in the absence of rheumatoid factor as well. The anti-CCP test 
has a similar sensitivity and a better specificity for RA than does rheumatoid factor. In 
individuals with early RA, assessment of anti-CCP may be the most useful to confirm the 
diagnosis. Anti-CCP’s most commonly occurs in persons with aggressive disease with a 
tendency for developing bone erosions, in those who smoke cigarettes and in those who are 
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associated with HLA beta-1 allele. it is a useful test to confirm a diagnosis of RA and to estimate 
prognosis. 
Normochromic, normocytic anemia is frequently present in active RA. It is due to 
ineffective erythropoiesis. Anemia and thrombocytosis correlate with disease activity. The white 
blood cell count is usually normal, but a mild leukocytosis can occur. Eosinophilia, when 
present, usually reflects severe systemic disease. The erythrocyte sedimentation rate (ESR) is 
increased in nearly all patients with active RA. Other acute-phase reactants including 
ceruloplasmin and C-reactive protein are also elevated, and generally such elevations correlate 
with disease activity and predict progressive joint damage.  
The synovial fluid is usually turbid, with reduced viscosity. Its protein content is 
increased and glucose concentration is slightly decreased or normal. The white cell count varies 
between 5 and 50,000/ µL and polymorphs predominate. Complements C3 and C4 are markedly 
diminished in synovial fluid as a result of activation of the classic complement pathway by 
locally produced immune complexes.  
 
RADIOGRAPHIC EVALUATION 
Early in the course of the disease radiographic evaluation reveals only soft tissue swelling 
and joint effusion. Juxtaarticular osteopenia, loss of articular cartilage and bone erosions develop 
after months of sustained activity. The primary value of radiography is to determine the extent of 
cartilage destruction and bone erosion and for monitoring the impact of therapy. 
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DIAGNOSIS 
The diagnosis of RA can be delayed due to the nonspecific nature of initial symptoms. A 
period of obse rvation may be necessary before the diagnosis can be established. A definitive 
diagnosis of RA depends mainly on the characteristic clinical features along with exclusion of 
other inflammatory processes. The isolated finding of a positive rheumatoid factor, anti-CCP 
antibody, or an elevated ESR or CRP should not itself be used as evidence of RA. 
The American College of Rheumatology developed revised criteria for the classification 
of RA in 1987. These criteria have a sensitivity of 91–94% and a specificity of 89% when used 
to classify patients with RA. Although these criteria were developed for investigational purposes, 
they can be used for establishing the diagnosis as well. Failure to meet these criteria does not 
exclude the diagnosis.  
ACR Revised Criteria for the Classification of RA (1987)6: 
1. Guidelines for classification 
a. Four of seven criteria are required to classify a patient as having rheumatoid arthritis 
(RA). 
b.  b. Patients with two or more clinical diagnoses are not excluded 
2.  Criteriaa  
a. Morning stiffness: Stiffness in and around the joints lasting 1 h before maximal 
improvement. 
12 
 
b.  Arthritis of three or more joint areas: At least three joint areas, observed by a 
physician simultaneously, have soft tissue swelling or joint effusions, not just bony 
overgrowth. The 14 possible joint areas involved are right or left proximal 
interphalangeal, metacarpophalangeal, wrist, elbow, knee, ankle, and 
metatarsophalangeal joints. 
c.  Arthritis of hand joints: Arthritis of wrist, metacarpophalangeal joint, or proximal 
interphalangeal joint. 
d. Symmetric arthritis: Simultaneous involvement of the same joint areas on both sides 
of the body. 
e. Rheumatoid nodules: Subcutaneous nodules over bony prominences, extensor 
surfaces, or juxtaarticular regions observed by a physician. 
f. Serum rheumatoid factor: Demonstration of abnormal amounts of serum rheumatoid 
factor by any method for which the result has been positive in less than 5% of normal 
control subjects 
g. Radiographic changes: Typical changes of RA on posteroanterior hand and wrist 
radiographs that must include erosions or unequivocal bony decalcification localized 
in or most marked adjacent to the involved joints. 
aCriteria a–d must be present for at least 6 weeks. Criteria b–e must be observed by a 
physician. 
RENAL INVOLVEMENT IN RHEUMATOID ARTHRITIS 
Renal involvement is generally considered to be quite rare, although RA is often 
characterized by the presence of rheumatoid factors and circulating immune complexes7. 
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Population-based studies have proven that patients with RA have an increased mortality relative 
to age-matched controls, and that this increased mortality has been attributed to renal disease8,9.  
Renal involvement in RA has been broadly classified into two broad categories: lesions caused 
by the disease itself and lesions occurring as a result of drugs used in the management of disease. 
Renal involvement in rheumatoid arthritis (RA): 
• Renal disorders related to RA: 
   Amyloidosis 
   Glomerular lesions 
   Vascular lesions 
   Tubulointerstitial lesions 
• Renal disorders related to drug therapy: 
   Nonsteroidal antiinflammatory drugs 
   Analgesics 
   Gold/penicillamine 
   Cyclosporine 
Prevalence and patterns of renal disease in rheumatoid arthritis: 
The prevalence of renal disease in rheumatoid arthritis has been examined using three types of 
study, based either on death certificates or on autopsy studies or renal biopsy studies. 
Interpretation of these studies is complicated by differences in the definitions of rheumatoid 
arthritis, the duration of disease at death, the treatment received, the accuracy of death 
certification, and the method of statistical analysis. 
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Incidence of renal disease in rheumatoid arthritis: Death certificate studies: 
Study Country Number  of patients 
Renal 
amyloid 
(%) 
Renal 
failure (%) 
Cobb et al. 
(1953)10 USA 130 3.1 10 
Rasker and Cosh 
(1981)11 UK 43 7 11.6 
Prior et al. 
(1984)12 UK 199 1.5 3.0 
Laasko et al. 
(1986)9 Finland 356 8.7 11.8 
Autopsy studies in rheumatoid arthritis: 
Study Country Number  of patients 
Renal 
amyloid 
(%) 
Renal failure 
(%) 
Missen and 
Taylor (1956)13 UK 47 17 - 
Mutru et al. 
(1976)14 Finland 41 17 27 
Ramirez et al. 
(1981)15 USA 76 8 9 
Boers et al. 
(1987)16 Holland 132 11 23 
Suzuki et al. 
(1994)17 Japan 81 21 9.9 
        In autopsy studies the proportion of patients with renal failure ranged from 9 to 27 per cent, 
and of renal amyloid from 8 to 17 per cent. The high prevalence of renal failure in the autopsy 
studies is at variance with clinical experience. In addition to renal amyloid, autopsy studies in the 
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1940s showed a proliferative glomerulonephritis. Some studies have shown a high incidence of 
glomerulonephritis and renal vasculitis. 
Renal biopsy studies in rheumatoid arthritis: 
Study 
Number 
of 
patients 
Clinical 
features Normal 
Mesangial 
proliferative 
Membra-
nous Amyloid 
Tubulo-
interstitial 
nephritis
Others 
Brun et 
al. 
(1965)18 
32 
Normal, 
proteinuria, 
renal 
impairment 
11 0 1 4 9 7 
Salomon 
et al. 
(1974)19 
18 
Normal, 
proteinuria, 
microscopic 
haematuria 
11 7 0 0 0 0 
Orjavik 
et al. 
(1981)20 
14 
Proteinuria, 
nephrotic 
syndrome 
0 5 0 7 0 2 
Sellars 
et al. 
(1983)21 
30 
Proteinuria, 
microscopic 
haematuria, 
nephrotic 
syndrome 
0 13 9 1 4 3 
Hordon 
et al. 
(1984)22 
21 Microscopic haematuria 1 15 1 0 1 3 
Helin et 
al. 
(1986)23 
39 
Proteinuria, 
nephrotic 
syndrome, 
renal 
impairment 
3 11 9 16 0 0 
Adu et 
al. 
(1993)24 
90 
Proteinuria, 
nephrotic 
syndrome, 
renal 
impairment 
0 10 18 13 14 35 
Korpela 
et al. 
(1990)25 
74 Not given 7 23 13 20 3 8 
Nakano 
et al. 
(1998)26 
158 
Proteinuria, 
nephrotic 
syndrome 
haematuria, 
renal 
impairment 
20 54 49 30 - 5 
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Renal biopsy studies have not provided evidence of a consistent pattern of renal disease. Most of 
the earlier studies included patients with minor urinary abnormalities and this explains the lesser 
incidence of glomerular diseases and more normal biopsies. The studies by Brun et al18 and 
Saloman et al19 nhad 11 normal biopsies each. Further studies identified the renal involvement 
secondary to drugs like gold and penicillamine. Later studies proved that glomerular diseases can 
also occur in patients who have not received gold or penicillamine.           
AMYLOIDOSIS 
Amyloidosis is a systemic disease characterized by deposition of an insoluble 
proteinaceous material in the extracellular matrix of multiple organs. These proteinaceous 
deposits have a unique fibrillar ultrastructure characterized by a rigid, nonbranching filament of 
about 100 Å in diameter. Amyloidosis is classified according to the type of fibril deposited –AA 
amyloidosis (secondary amyloidosis) which occurs as a result of chronic inflammatory response 
and AL amyloidosis (primary amyloidosis) which is usually associated with plasma cell 
dyscrasias. 
Rheumatoid arthritis and juvenile chronic arthritis are the most common causes of AA 
amyloidosis in developed countries. Rheumatoid arthritis-associated AA amyloid is more 
common in Europe and Japan. There has been a decline in prevalence of RA associated amyloid 
in the last 20 years, particularly more so in the last 5 years. The reason for this declining trend 
could be attributed to much more aggressive therapy which reduces the persistently elevated 
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acute phase response. Proteinuria, often with a nephrotic syndrome, is the most common clinical 
presentation. Other presentation includes either acute or chronic kidney disease.  
 
PATHOLOGY OF AMYLOIDOSIS: 
The diagnosis of amyloid in RA is based on histological examination of rectal biopsy or 
abdominal fat pad biopsy. In patients with renal abnormalities a renal biopsy is indicated. Renal 
biopsy reveals an amorphous acellular material that is periodic-acid Schiff negative. When 
stained with congo red stain and examined under polarized light, a characteristic apple green 
birefringence is noted. Congo red staining in AA amyloid is sensitive to potassium permanganate 
unlike AL amyloid which is resistant. Immunohistochemistry using antibodies to 
immunoglobulin light chains may also confirm AL amyloid. 
 
CLINICAL COURSE AND TREATMENT OF AMYLOIDOSIS 
Amyloidosis is usually seen in with patients with long-standing RA (>10 years duration) 
and is also more common in patients who are positive for rheumatoid factor (RF) and who have 
significant joint destruction. The clinical course of AA amyloidosis in patients with RA is 
usually progressive, as there are no satisfactory treatments aside from aggressive treatment of the 
underlying disorder. In a randomized controlled trial, Ahlmen et al27 reported a 5-year patient 
survival of 89 per cent in patients who received cytotoxics as compared to 29 per cent in 
untreated patients. Elkayam et al reported resolution of proteinuria and stabilization of amyloid 
deposits by serial 123I-labeled serum amyloid P scintigraphy in a woman with rheumatoid 
arthritis of 10 years duration and proteinuria (900 mg per 24 hours) treated with infliximab.28 It 
is now evident that aggressive management of active joint inflammation may decrease the 
frequency and severity of AA amyloidosis in patients with RA. Poor prognostic factors include 
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cardiac involvement and serum creatinine level greater than 2.0 mg/dL at presentation.29 Also 
patients with amyloidosis generally do poorly on dialysis, and recurrence of amyloid deposits has 
been reported in transplanted kidneys.30 
PROLIFERATIVE GLOMERULONEPHRITIS 
Focal or diffuse endocapillary proliferative glomerulonephritis is rare in rheumatoid arthritis. In 
the study by Boers et al,16 only 5 of 132 cases had a proliferative glomerulonephritis (diffuse in 
one and focal in four).  Davis et al31 reported a case of proliferative glomerulonephritis in whom 
the renal biopsy showed mesangial hypercellularity and proliferative changes in the glomeruli, 
and electron microscopy revealed subendothelial deposits. Ramirez et al15 identified 3 cases of 
proliferative glomerulonephritis in 76 renal biopsies. Helin et al32 reported 4 cases of 
proliferative glomerulonephritis out of 110 biopsies. Despite the presence of circulating immune 
complexes, proliferative glomerulonephritis is not seen commonly in RA. It is considered that 
the circulating immune complexes in RA might have reduced complement fixing ability. 
MESANGIAL PROLIFERATIVE GLOMERULOPATHY 
Several studies in patients with RA and microscopic haematuria have reported a mild mesangial 
proliferative glomerulonephritis. Mesangial proliferation is the most common renal lesion 
identified in patients with RA.19,21,22,25,26 This lesion is characterized by increased mesangial 
matrix and hypercellularity and mesangial deposits of IgM, IgA, and C3.33  Forty out of 110 
patients in the study by Helin et al32 and 54 out of 158 by Nakano et al26 had mesangial 
proliferation. Despite the findings of glomerulitis on renal biopsy, the clinical consequences of 
these lesions are minor. The most frequent manifestations of mesangial proliferative 
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glomerulopathy in RA are microscopic hematuria and low-grade proteinuria. Follow-up of these 
patients has shown a benign course and progression to renal insufficiency and/or increasing of 
proteinuria is very rare32. 
IGA NEPHROPATHY 
In the studies of Sellars et al21, Helin et al23, and Korpela et al25, several patients described with a 
mesangial proliferative glomerulonephritis had mesangial IgA deposits. In a Japanese study, 
Nakano et al26 reported a very high incidence of IgA nephropathy, with 26 out of 158 patients 
who underwent biopsies revealed mesangial IgA deposits. As in idiopathic IgA nephropathy, the 
pathogenetic mechanisms of this disorder in patients with RA are unclear. To clarify the 
pathogenesis of IgA glomerulopathy in patients with RA, Nakano et al34 examined class specific 
rheumatoid factors, including IgA-RF. There was little correlation between histopathological 
findings and the serum concentration of any class of RF, although the mean IgA-RF 
concentration was slightly higher in patients wth IgA glomerulopathy than in the group with non-
IgA glomerular diseases. Certain genetic or geographic factors have also been related to the 
onset of primary IgA nephropathy. A significant association has been identified between HLA-
DR4 and primary IgA nephropathy35. HLA-DR4 antigen is also thought to be related to the 
occurrence and progression of RA36. Therefore, a common pathogenetic basis may exist that 
explains the ocurrence of RA and IgA nephropathy. However, because IgA nephropathy is the 
most common primary glomerular disease in the Japanese population, the prevalence of IgA 
nephropathy in RA in the study by Nakano et al26 may be related to the high frequency of IgA 
glomerulopathy in the Japanese population. The results of this study should be interpreted with 
caution when applying to the general population. 
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MEMBRANOUS NEPHROPATHY 
The most common cause of membranous nephropathy in patients with rheumatoid arthritis is 
gold or penicillamine therapy. However, there are now many reports of such patients who had 
never been on gold or penicillamine, and who have a membranous nephropathy unrelated to drug 
treatment. The numbers of reported cases make it unlikely that this association is coincidental. 
Honkanen et al37 reported on four patients with rheumatoid arthritis and membranous 
nephropathy, and reviewed the literature. Only one of their four patients had received gold and 
that was 16 years before the renal biopsy.  Adu et al24 observed six patients with rheumatoid 
arthritis and membranous nephropathy, none of whom had been treated with penicillamine, 
although two had received gold that was discontinued 17 and 13 years before renal biopsy. 
Membranous nephropathy in the setting of an auto-immune disease might be secondary to 
systemic lupus erythematosus(SLE), hence it seems prudent to rule out SLE in RA associated 
membranous nephropathy.  None of the patients in the reports by Honkanen et al and Adu et al, 
had clinical or serological evidence of SLE. 
GLOMERULAR BASEMENT MEMBRANE IN RA 
Saito et al38 reported a study on the thickness of glomerular basement membrane. He 
compared thickness of the glomerular basement membrane in 48 RA patients as against 10 
controls after ruling out hereditary thin basement membrane disease and secondary glomerular 
diseases. The mean GBM thickness was found to be significantly thinner in RA patients as 
against the control group. However, the authors found that the mean GBM thickness of RA 
patients without gold sodium thiomalate treatment (GST) was not statistically different from the 
control group, while RA patients who received GST had significantly thinner GBM as compared 
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to controls. This led the authors to conclude that the thinning of GBM in RA may be related to 
GST treatment. 
 VASCULITIS IN RA 
The clinical spectrum of rheumatoid arthritis includes a systemic vasculitis, with involvement of 
blood vessels ranging in size from capillaries to small- and medium-sized arteries. The clinical 
presentation includes nailfold infarcts, a leucocytoclastic vasculitis, a peripheral neuropathy, 
pericarditis, gastrointestinal infarcts, and renal vasculitis. Data registry from Norwich Health 
Authority in the United Kingdom suggests an annual incidence of systemic rheumatoid vasculitis 
of 12.5 per million population39. 
Pathogenesis 
The pathogenesis of vasculitic glomerulonephritis in rheumatoid arthritis is unknown. The 
majority of renal biopsies in the patients with this lesion show no significant immune deposits40. 
This pauci-immune vasculitic glomerulonephritis is similar to that seen in microscopic 
polyangiitis and Wegener's granulomatosis. Several patients with rheumatoid arthritis and a 
vasculitic glomerulonephritis have had antineutrophil cytoplasmic antibodies (ANCA) and in 
some studies these were directed against myeloperoxidase41. It is, however, difficult to establish 
a pathogenic role for ANCA in rheumatoid vasculitis. The prevalence of ANCA positivity in RA 
patients varies from 20 -40 per cent42,43. Coremans et al, reported antilactoferrin antibodies in 
patients with RA associated vasculitis44.  
Pathology 
In an autopsy study by Boers et al,16 of 132 patients with rheumatoid disease found a large vessel 
renal vasculitis in 8 of 18 cases with systemic vasculitis, and in four patients there was an 
extracapillary proliferative glomerulonephritis. There are now several case reports and small 
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series of necrotizing and crescentic glomerulonephritis in patients with rheumatoid arthritis 
(Breedveld et al. 1985; Kuznetsky et al. 1986; Harper et al. 1997; Messiaen et al. 1998; Yorioka 
et al. 1999; Qarni and Kohan 2000). The renal pathology is of a vasculitic glomerulonephritis 
with focal and segmental necrosis of glomerular capillaries, breaks in the capillary walls, and 
extracapillary proliferation with a crescentic glomerulonephritis (Kuznetsky et al. 1986; Harper  
et al. 1997; Messiaen et al. 1998) (Fig. 2). Only 23 per cent of renal biopsies show significant 
glomerular immune deposits. An extraglomerular renal vasculitis is found in only 12 per cent of 
cases. Occasional patients may have other glomerular lesions such as a membranous 
nephropathy (Kuznetsky et al. 1986; Harper et al. 1997) or amyloidosis (Kiyama et al. 1991; 
Harper et al. 1997). Similar glomerular lesions have also been reported in patients with 
rheumatoid arthritis and other disorders who were treated with penicillamine. 
Clinical presentation 
The median age at onset from the published studies was 62 years with a range of 22â€“76 years 
and the median duration of rheumatoid arthritis of 13 years (range 1â€“40 years). Both genders 
are equally affected. Eighty-five per cent of patients are seropositive and 50 per cent of patients 
have extrarenal vasculitis. The clinical presentation is with microscopic haematuria and 
proteinuria in 90 per cent of cases and all patients have renal impairment or renal failure, which 
may be severe enough to require dialysis. 
Treatment and outcome 
Treatment is with prednisolone and cyclophosphamide in the doses used to treat microscopic 
polyangiitis (see Chapter 4.5.3). The prognosis is reasonable with 95 per cent of patients 
surviving the acute illness. However, renal failure may be irreversible and require long-term 
dialysis. These studies show that, in addition to a renal arteritis, patients with rheumatoid arthritis 
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may develop a vasculitic glomerulonephritis that by light microscopy appears similar to that seen 
in microscopic polyarteritis and Wegener's granulomatosis. 
 
RENAL DISEASES RELATED TO DRUG THERAPY 
NONSTEROIDAL ANTIINFLAMMATORY DRUGS 
Nonsteroidal antiinflammatory drugs (NSAIDs) remain the backbone of rheumatoid 
arthritis therapy. Their anti-inflammatory effect is mediated by inhibition of cyclooxygenase, 
which is involved in synthesis of prostaglandins. Inhibition of renal prostaglandin synthesis 
results in reduced glomerular blood flow57,58. In addition to this hemodynamically mediated 
action, NSAIDs can also cause interstitial nephritis. Interstitial nephritis is usually reversible and 
recovery occurs when the drugs are discontinued. The selective cyclooxygenase-2 inhibitors also 
have the same adverse effects on renal function, as do other NSAIDs. When a patient with RA 
presents with evidence of decreased renal function or interstitial changes, discontinuation of 
NSAIDs should be the first step taken in the management protocol. Analgesic nephropathy is a 
combination of papillary necrosis and interstitial nephritis. It usually occurred with phenacetin. It 
can also occur with ibuprofen, phenylbutazone, naproxen, and mefenamic acid particularly when 
used in combination. 
 
RENAL LESIONS ASSOCIATED WITH GOLD THERAPY 
The use of gold salts in the treatment of RA was first described by Forestier in 1935. 
With the availability of newer agents, gold treatment is used less often now. The hallmark of 
renal toxicity from gold is proteinuria, occurring in 3% to 10% of RA patients. Proteinuria 
usually occurs 4 to 6 months after the initiation of gold therapy. The severity of proteinuria is 
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usually not proportional to the dose of gold received. The proteinuria resolves gradually with 
discontinuation of gold59, steroids were not required. The renal histology associated with gold-
induced proteinuria is membranous glomerulopathy. Light microscopy shows uniform basement 
membrane thickening, and electron microscopy shows subepithelial deposits. Gold-induced 
proteinuria is common in patients with the HLA antigens B8 and DR360.  
 
RENAL LESIONS ASSOCIATED WITH PENICILLAMINE THERAPY 
Penicillamine was introduced in the 1950s for the treatment of Wilson's disease. Later it 
has been tried in RA and used widely until methotrexate became available. It is a slow-acting 
drug and usually takes 3 to 6 months for responses to occur. Penicillamine induced nephropathy 
is similar to gold nephropathy and causes hematuria and/or proteinuria. Because it is a slowly 
acting drug, the onset of proteinuria is also delayed with an average of 8 months of initiation of 
therapy. After the discontinuation of penicillamine, proteinuria resolves spontaneously. No 
steroid therapy is warranted as spontaneous remission is the rule61. Histologically, penicillamine-
induced renal lesions manifests as membranous nephropathy. Apart from causing membranous 
nephropathy, penicillamine causes a wide variety of renal lesions. It induces antibodies to 
histones to result in drug induced lupus, it also triggers anti neutrophilic cytoplasmic antibodies 
to result in vasculitis that may even present as rapidly progressive crescentic 
glomerulonephritis62. Penicillamine-induced crescentic glomerulonephritis requires aggressive 
immunosuppressive therapy. Clinical picture of Goodpasture's syndrome has also been reported 
following penicillamine therapy63.  
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RENAL LESIONS ASSOCIATED WITH METHOTREXATE AND OTHER DMARD 
THERAPY 
Methotrexate is a folic acid antagonist and is one of the major DMARD used in the 
treatment of RA. Methotrexate when used in high doses in the treatment of malignancies has 
been associated with renal failure. But renal failure is extremely rare, when methotrexate is used 
in low doses (5 to 25 mg/week) to treat RA. On the other hand, renal failure can significantly 
alter the metabolism of methotrexate and increase its toxicity64. Hence methotrexate needs dose 
reduction in renal failure and better avoided in severe renal dysfunction. Renal function has to be 
monitored regularly in those patients taking methotrexate and having mild renal insufficiency. 
Other commonly used DMARDs such as hydroxychloroquine, azathioprine, leflunomide, 
sulfasalazine and the newer biologic agents like etanercept and infliximab does not have 
nephrotoxicity65.             
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MATERIALS AND METHODS 
 
Study centre : Rajiv Gandhi Government General Hospital and Madras Medical College, 
Chennai. 
Study Design : Prospective observational study. 
Study period : September 2010 to February 2013. 
INCLUSION CRITERIA:   
1. Rheumatoid arthritis was diagnosed by rheumatologist and all the patients fulfilled 
the American College of Rheumatology Revised Criteria for the Classification of RA 
(1987)6.  
2. All Rheumatoid Arthritis patients attending rheumatology clinic were considered for 
screening and those patients who had abnormal urine sediments (RBC’s, RBC Cast) 
or proteinuria (>0.3gm/day) or raised serum creatinine (>1.2mg/dl) will be included 
in the study. 
3. Patients who were both sero-positive and sero-negative for rheumatoid factor were 
included. 
4. Apart from screening, those patients who have been referred from rheumatology 
department for abnormal urine sediments or raised serum creatinine were also 
included. 
EXCLUSION CRITERIA: 
1.  Patients who had normal urine analysis and normal serum creatinine were excluded 
from the study. 
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2. Rheumatoid Arthritis patients with diabetes mellitus, hepatitis B and C, human 
immunodeficiency virus, syphilis and other diseases known to cause glomerular 
pathology were excluded from the study. 
METHODS 
All rheumatoid arthritis patients were subjected to screening tests which included urine 
analysis and blood urea and serum creatinine estimation. Urine analysis, blood urea and serum 
creatinine estimation were done at renal lab, department of nephrology.  
1. HISTORY 
Age and sex of the patient was noted. Duration of rheumatoid arthritis, drug history with 
special interest to duration of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), methotrexate 
and other Disease Modifying Anti-Rheumatic Drugs(DMARDs) were noted. Consumption of 
indigenous medicines was also probed. Symptoms of joint pain, joint swelling, edema legs, 
oliguria and hematuria were noted. History of hypertension was also noted. 
2. EXAMINATION 
Height and weight of the patient was recorded. Blood pressure was recorded thrice and 
the average taken. Presence of joint swelling, tenderness and deformities were noted. General 
examination was made with special interest to lymphadenopathy, subcutaneous nodules and 
purpuric spots over extremities or vasculitic ulcers. Complete systemic examination were done.  
3. URINE ANALYSIS 
Microhematuria is defined as more than or equal to 5 RBC’s per high power field. 
Proteinuria is quantified by spot urine protein to creatinine ratio (PCR). Nephrotic syndrome is 
defined as urine PCR more than 3.5. Sub-Nephrotic proteinuria is used when urine PCR is 
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between 1 and 3.5. Those with urine PCR between 0.3 and 1 were also included in the study to 
assess the clinic-pathologic correlation. Urine culture was also done for all patients. 
4. BLOOD INVESTIGATIONS 
Complete hemogram including hemoglobin, total and differential WBC count, 
Erythrocyte Sedimentation Rate (ESR) and platelet count were done. Random blood sugar was 
done in all cases and fasting and post-prandial blood sugar was done when appropriate. Blood 
urea, serum creatinine and electrolytes, serum complements C3 and C4 were also done. 
5. RHEUMATOID FACTOR AND C-REACTIVE PROTEIN 
Rheumatoid factor (RF) and C- Reactive Protein (CRP) was done in rheumatology lab. 
Rheumatoid factor was done by latex agglutination method and a value of more than 8 IU/ml 
was considered positive. The test will be repeated in higher titres and the maximum titre is given 
as more than 256 IU/ml. CRP was done by nephelometry and values are expressed in mg/L. CRP 
of more than 6 mg/L was considered positive. Antibodies to cyclic citrullinated peptides (anti-
CCP) was done only in selected patients to confirm the diagnosis. It was done by ELISA and 
values more than 6.5 IU/ml is considered positive. 
6. RADIOLOGIC INVESTIGATIONS 
Chest X-ray was taken for all patients. Ultrasonogram of the kidney, ureter and bladder 
was done with full bladder in all patients. Kidney size, echoes, cortico-medullary differentiation 
and pelvi-calyceal system were noted. 
After getting the Ultrasonogram, those with normal sized kidneys with urinary 
abnormalities and/or raised serum creatinine were subjected for renal biopsy. Those with kidneys 
of size less than 8 cm or those with grade III increased echoes and poor cortico-medullary 
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differentiation with raised serum creatinine were labeled as chronic kidney disease at entry into 
study and biopsy was deferred in this group. 
7. RENAL BIOPSY 
After getting informed consent for percutaneous renal biopsy, bleeding time, clotting 
time, prothrombin time, International Normalised ratio (INR) were done to ensure normal 
bleeding and clotting profile. The position and depth of the left kidney was marked with bed side 
Ultrasonogram. After ensuring strict asepsis, under local anaesthesia, percutaneous renal biopsy 
was done using 18G automatic spring loaded biopsy gun (BARD biopsy gun). Two tissues were 
taken. One is preserved in formalin for light microscopy and the other in Michel’s fixative for 
immunoflourescence study. In light microscopy, sections are studied with Hematoxylin and 
eosin, Per-iodic acid Schiff and Masson’s trichrome stain for all specimens. Silver, congo red 
and other special stains were applied as appropriate. Immunofluorescence was studied for IgA, 
IgM, IgG, C3, C1q and for kappa (κ) and lambda (λ) light chains. Immunohistochemistry was 
also used in special circumstances like detection of AA in case of amyloidosis. Post biopsy 
patient was observed for hematuria, hypotension and loin pain. 
FOLLOW UP 
The patients were followed up for 3 to 28 months (mean 15 months). All Patients were followed 
up every 2 weeks. At follow up, urine analysis, urine PCR, hemogram and serum creatinine was 
done in all cases. For those who had proteinuria at presentation, the following definitions were 
used at follow up. 
Complete remission: urine spot protein- creatinine ratio less than 0.3 
Partial remission: urine spot protein- creatinine ratio less than 1 or 50% reduction from baseline 
value during follow up. 
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ESTIMATED GLOMERULAR FILTRATION RATE 
Estimated glomerular filtration rate (eGFR) was calculated using CockCroft-Gault equation: 
Estimated Creatinine  =     (140 – age ) x body weight (kg ) 
clearance(ml/min)              72 x serum creatinine (mg / dl) 
 
This equation is for men. It is multiplied by 0.85 for women. 
 
STATISTICAL ANALYSIS 
 Statistical analyses were done using Graphpad software. Patient demographics were 
presented as mean, median and range. Univariate analyses were done by Fisher’s exact test and 
two tailed Student’s t test and p-value less than 0.05 were considered significant. 
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RESULTS 
  The study population included patients referred to the department of nephrology as well 
as patients who were screened at the department of Rheumatology. Total number of patients 
screened was 300.  Out of this 300 patients, 27 were asymptomatic and was detected to have 
either urinary abnormalities or raised serum creatinine without urinary abnormalities only on 
screening. About 25 patients were symptomatic and had been referred to the department of 
nephrology for urinary abnormalities or raised serum creatinine or both. Hence total number of 
patients included for final analysis was 52, of which females were 31 as shown in table – 1. 
TABLE – 1 
TOTAL NUMBER OF PATIENTS INCLUDED 
IN THE STUDY 
52 
FEMALE : MALE 1.5 : 1 
 
AGE DISTRIBUTION: 
The age distribution ranged from 18 to 67 years, with mean + SD being 45.17 + 11.7 years. Most 
of the individuals were in the third and fourth decade. 
 
 
 
 
 
 
 
 
TABLE – 2 
AGE GROUP N 
Less than20 1 
21 – 30 5 
31 – 40 13 
41 – 50 16 
51 – 60 12 
More than 60 5 
Total 52 
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PATIENT CHARACTERISTICS: 
The duration of illness in our patients at the entry of study varied from 6 months to 30 years, 
with the mean of 8.5 years. About 80 percent of them had positive rheumatoid factor (RF). 
Hypertension was noted in 11 patients (21.2%) as shown in table – 3. Extra-renal symptoms and 
signs and joint deformities are summarized in tables 4 and 5 respectively. 
 
TABLE – 3 
Mean duration of RA (years) 8.5 
Rheumatoid factor positivity –N(%) 42 (80.7%) 
Mean ESR (mm in 1st Hr) 54.8 
Mean CRP (mg/L) 10.6 
Hypertension - N(%) 11 (21.2%) 
Diabetes mellitus- N 0 
  
 
TABLE – 4 : EXTRA-RENAL SYMPTOMS/SIGNS: 
FEATURES N(%) 
1.Joint pain 47 (90.3%) 
2.Early morning stiffness 50 (96%) 
3.Fever  6 (11.5%) 
4.Subcutaneous nodules      9 (17.3%) 
5. Joint deformities 28 (53.8%) 
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TABLE – 5 :  JOINT DEFORMITIES 
Hallux valgus  1 
Swan-neck deformity 2 
Boutonniere deformity 2 
Ulnar deviation of hand 2 
Multiple small joint arthritis of hand 21 
 
TREATMENT HISTORY: 
Almost all patients except two were on steroid therapy at the entry of study. Two patients 
had joint pain and early morning stiffness for more than 6 months, but presented with nephritic 
syndrome. They were diagnosed to have rheumatoid arthritis during the evaluation of renal 
disease. Hence they were not on steroids and NSAIDS at diagnosis of renal disease. All other 
patients were on tablet prednisolone 5 to 10 mg per day. Except these two patients all other 
patients were on NSAIDS as well, until they were diagnosed to have renal disease. The most 
commonly used NSAID was tablet Indomethacin 2 to 3 mg per Kg per day. About 23 patients 
were on Methotrexate therapy. The dose of Methotrexate ranged from 7.5 mg to 20 mg per week. 
Hydroxychloroquine was used in 18 patients, while 9 patients received a combination of 
Hydroxychloroquine and Methotrexate. 
TABLE – 6 
Pt’s receiving prednisolone N(%) 
     -Dose in mg/day (median) 
50 (96%) 
10 
Pt’s receiving Methotrexate N(%) 
-Dose in mg/week (median) 
23 (44.2%) 
7.5 
Pt’s receiving Hydroxychloroquine N(%) 
     -Dose in mg/ day (median) 
18 (35%) 
200 
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CLINICAL PRESENTATION: 
The common symptom at presentation was edema of the legs followed by hypertension and 
oliguria. Two patients presented with macrohematuria. About 27 patients did not have any renal 
symptoms and was detected to have either urinary abnormalities or raised serum creatinine only 
by screening. The clinical presentation is summarized in table – 7. 
 
TABLE – 7  
Clinical feature N(%) 
Edema  15 (28.8%) 
Oliguria  7 (13.4%) 
Macrohematuria  2 (3.8%) 
Asymptomatic  27 (51.9%) 
 
 
The various renal syndromes with which the patients presented is depicted in table -8 
TABLE – 8 
RENAL SYNDROME N(%) 
Nephrotic syndrome 8 (13.4%) 
Nephritic syndrome 4 (7.6%) 
Asymptomatic urinary abnormalities 12 (23%) 
Acute kidney injury 2 (3.8%) 
Hypertension  11 (21.2%) 
Chronic kidney disease 23 (44.2%) 
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The proportion of patients with urinary abnormalities including proteinuria, microhematuria and 
renal failure at presentation is classified in table – 9. 
 
TABLE – 9 
FEATURE N (%) 
Microhematuria 4 (7.6%) 
Nephrotic range proteinuria without renal 
dysfunction  
5 (9.6%) 
Nephrotic range proteinuria with renal 
dysfunction 
3 (5.8%) 
Proteinuria ( sub-nephrotic) without renal 
dysfunction 
13 (25%) 
Proteinuria ( sub-nephrotic) with renal 
dysfunction 
2 (3.8%) 
Renal failure without urinary abnormalities 23 (44.2%) 
 
RENAL BIOPSY: 
At entry into study, about 23 patients (44%) had evidence of chronic kidney disease in 
the form of raised serum creatinine with Ultrasonogram showing reduced kidney size with grade 
III echoes or poor cortico- medullary junction. Rest of the patients(n=29) had normal sized 
kidneys and presented with proteinuria and/or nephritic syndrome or acute kidney injury. All of 
these 29 patients underwent renal biopsy. The two patients who had acute kidney injury had 
acute interstitial nephritis and acute tubular necrosis. The remainder of patients had glomerular 
diseases identified in biopsy. The most common lesion noted was mesangial proliferative 
glomerulopathy, followed by focal endocapillary proliferative glomerulonephritis. 
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TUBULO-INTERSTITIUM AND VASCULAR COMPARTMENT: 
  Tubulo-interstitium was normal in 19 cases. The renal biopsy in the two cases of acute 
kidney injury showed lymphocytic infiltrates suggestive of acute interstitial nephritis in one and 
acute tubular injury (previously acute tubular necrosis) in the other. Interstitial fibrosis with 
tubular atrophy (varied from 10 to 50%) was noted in 3 cases.  Blood vessels were thickened in 7 
patients out of which only 1 had hypertension. The remaining 6 patients had vascular changes in 
the absence of hypertension. Fibro-intimal proliferation of blood vessels were seen in 2 cases.  
TABLE – 10 
Renal histology  N 
1.Mesangial proliferative glomerulopathy 9 
2.Focal endocapillary proliferative  glomerulonephritis  5 
3.IgA nephropathy 3 
4.Minimal change disease 2 
5.Membranous nephropathy 2 
6.Amyloidosis 2 
7.Focal segmental glomerulosclerosis 2 
8. Nodular glomerulosclerosis  1 
9.Ischemic glomerulosclerosis 1 
10. Acute interstitial nephritis 1 
11.Acute tubular injury 1 
12.Total  29 
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IMMUNOFLUORESCENCE MICROSCOPY: 
Dominant or Co-dominant mesangial deposits of IgA were found in 3 cases. The 
immunoflourescence pattern in other glomerular diseases is shown in table-11.  
 
TABLE – 11 
GLOMERULAR DISEASE IMMUNOFLUORESCENCE 
PATTERN (IF) 
No. of 
cases 
Mesangial proliferative glomerulopathy 
(n= 9) 
IgM and C3  
IgM, C3 and C1q 
IgM alone  
IgG alone  
C3 alone  
5 
1 
1 
1 
1 
Focal endocapillary proliferative  
glomerulonephritis 
(n= 5) 
IgG and C3  
IgG, IgA and C3  
IgM and C3  
C3 alone  
2 
1 
1 
1 
Membranous nephropathy  
(n= 2) 
IgG and C3  
IgG, IgM and C3  
1 
1 
Focal segmental glomerulosclerosis 
(n=2) 
IgM and C3  
IgM alone  
1 
1 
Ischemic glomerulosclerosis (n =1) C3 alone  1 
Amyloidosis (n=2) 
Minimal change disease (n= 2) 
Nodular glomerulosclerosis (n = 1) 
No IF deposits  
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RENAL HISTOPATHOLOGY AND CLINICAL PRESENTATION 
Among 29 patients who underwent biopsy, 8 presented with oedema legs and had 
nephrotic range proteinuria. Out of these 8 patients, 3 had evidence of renal dysfunction (eGFR < 
60 ml/mt) at presentation. The histopathology in the cohort of nephrotic syndrome included, 
membranous nephropathy, amyloidosis and focal segmental glomerulosclerosis – 2 cases each, 
followed by minimal change disease and nodular glomerulosclerosis - 1 case each. The 
histopathology in nephritic syndrome was consistent with focal proliferative glomerulonephritis 
in 3 cases and IgA nephropathy in 1 case. About 12 patients did not have edema legs and had 
subnephrotic proteinuria on urine examination. They were classified as those with asympomatic 
urinary abnormalities. The most common biopsy finding in this group was mesangial 
proliferation followed by IgA nephropathy, focal endocapillary proliferative glomerulonephritis 
and minimal change disease.  
Patients with focal proliferative glomerulonephritis and minimal change disease with 
nephrotic range proteinuria received oral prednisolone therapy. Out of 5 patients with focal 
proliferative glomerulonephritis, 1 had complete remission of proteinuria and recovery of renal 
dysfunction, 3 had partial remission while 1 patient who had sclerosing glomerulonephritis in 
addition to focal endocapillary proliferative glomerulonephritis progressed to chronic kidney 
disease and became dialysis dependent within 3 months. Out of 2 patients with minimal change 
disease, 1 had complete remission and the other had partial remission. Patients with amyloidosis, 
membranous nephropathy and mesangial proliferation received anti- proteinuric measures with 
angiotensin converting enzyme inhibitors and statins. Out of 9 patients with mesangial 
proliferative glomerulopathy, 3 patients achieved complete remission, remaining 6 continued to 
have proteinuria during follow up. 
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TABLE –12. CLINICO-PATHOLOGIC CORRELATION 
Renal 
histology 
Proteinuria 
(Urine PCR 
– 1 to 3.5) 
Nephrotic 
syndrome Hematuria Hypertension 
Renal 
failure 
Mes PG 
(n=9) 9 - - 1 1 
Foc EPGN 
(n=5) 5 - 3 2 2 
IgA 
Nephropathy 
(n=3) 
3 - 1 1 - 
MN 
(n=2) - 2 - 1 - 
Amyloidosis 
(n=2) - 2 - - 1 
MCD 
(n=2) 1 1 - - - 
FSGS 
(n=2) - 2 - - - 
Others 
(n=2) 1 1 -  2 
 
TABLE–13.  GLOMERULAR DISEASES – OUTCOME 
Renal histology Partial Remission 
Complete     
remission 
Persistent 
Proteinuria 
Persistent 
Hematuria 
Renal 
failure at 
follow up 
Mes PG 
(n=9) - 3 6 - - 
Foc EPGN 
(n=5) 3 1 1 - 
1 (Dialysis  
dependent)
IgA Nephropathy 
(n=3) 1 - 2 - - 
MN 
(n=2) 1 1 - - - 
Amyloidosis 
(n=2) - - 2 - 1 
MCD 
(n=2) 1 1 - - - 
FSGS 
(n=2) 1 - 1 - - 
Others 
(n=2) - - 2 - 2 
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RISK FACTORS FOR PERSISTENT PROTEINURIA 
About 27 patients who had glomerular disease in biopsy were followed up and found that 
proteinuria was persistent in 14 patients. Among remaining 13 patients, 6 had complete 
remission and 7 had partial remission. Risk factors contributing to persistent proteinuria were 
analyzed and presented in table – 14. The more the duration of the disease and more the ESR at 
presentation and follow up were significantly associated with persistent proteinuria. While C-
Reactive protein was also high in the persistent proteinuria group, it did not achieve statistical 
significance in the present study. Patient’s age and gender did not really predict remission of 
proteinuria. The basic pathology also correlated well with persistent proteinuria as seen with 
amyloidosis and FSGS. But the number is too meager that statistics could not be considered.    
 
 
TABLE – 14 :  
ANALYSIS OF FACTORS PREDICTING PERSISTENT PROTEINURIA 
Factors 
Proteinuria 
remitted 
(n=13) 
Persistent 
proteinuria 
(n=14) 
p – value 
Mean age (years) 41.3 39.2 0.62* 
Female: Male 11/2 (5.5 : 1) 8/6 (1.3 : 1) 0.2# 
Mean duration of RA 
(Years) 3.61 10.9 0.03* 
Mean ESR ( mm in 1st Hr) 33.8 73.2 0.0001* 
Mean CRP (mg/L) 10.22 12.95 0.106* 
*- Unpaired t test;   #- Fisher’s exact test 
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CHRONIC KIDNEY DISEASE AT PRESENTATION 
About 23 patients presented with chronic kidney disease at entry into study. This cohort 
had about 12 males and 11 females. All of these patients had no urinary abnormalities. Their 
ultrasonogram of the kidneys showed grade III echoes and altered cortico-medullary junction. 
Hence renal biopsy was not considered in these patients. The profile of this group is shown in the 
following table. 
TABLE – 15 
Patients with chronic kidney disease N (%) 23 (44.2%) 
Age in years (mean + SD) 50 + 10.3 
Male : Female 1 : 1 
Duration of rheumatoid arthritis  in years (Mean) 11.1 
Mean C- Reactive Protein (mg/L)  8.9 
Mean Serum creatinine at entry (mg/dl) 2.0 
Mean eGFR at entry ( ml/mt/1.73m2) 36.5 
Mean serum creatinine at follow up (mg/dl) 2.46 
Mean eGFR at follow up ( ml/mt/1.73m2) 31.1 
 
 Most of the patients were in CKD stage III B according to the latest KDIGO - CKD 
classification. On follow up, only 7 out of 23 showed a significant decrease in eGFR and 
worsened to the next stage of CKD. Rest of the patients remained in the same stage with 
relatively stable GFR. None of the patient reached stage V CKD. The proportion of patients in 
various stages of CKD is shown in table - 16 
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TABLE – 16 
CKD- STAGE 
Number of patients (n = 23) 
At entry At follow up 
I - - 
II 1 - 
IIIA 2 2 
IIIB 15 10 
IV 5 11 
V - - 
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DISCUSSION 
Renal involvement in rheumatoid arthritis (RA) can remain asymptomatic as evidenced 
by the present study in which about 27 patients (52%) did not have renal symptoms and they 
have been detected to have either urinary abnormalities or raised serum creatinine or both only 
on screening. The mean age group of patients studied was 45.1 years, with a peak in the third and 
fourth decade. The female: male ratio in the present study was 1.5 : 1, which is slightly less than 
the usually reported ratio1 of 2.5 : 1. The duration of illness varied from 6 months to 30 years 
with a mean of 8.5 years. The renal involvement in RA increases proportionally with the 
duration of the disease as evidenced by more occurrence of microalbuminuria in those with 
longer duration of disease45. Almost all patients had elevated ESR at entry into study with a 
mean of 54.8 mm in 1 hour. The mean C- reactive protein was also high at 10.6 mg/L. Raised 
ESR and CRP suggests increased disease activity and the more likelihood of developing renal 
disease. 
CLINICAL PRESENTATION 
 About 52% of patients were asymptomatic at the entry into study. The most common 
symptom was edema of the legs (29%), followed by reduced urine output (13.4%). 
Macrohematuria was rare and occurred in only 2 out of 52 cases (3.8%). Hypertension was 
detected in 11 patients (21%). In the necropsy series reported by Boers et al16, which included 
132 cases, about 26 (19.7%) had urine abnormalities with normal renal function and 27 (20.5%) 
had normal urine with loss of renal function.  
 About 8 patients (13.4%) presented with nephrotic syndrome, of which 3 patients also 
had evidence of renal dysfunction. About 4 patients (7.6%) presented with nephritic syndrome 
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with evidence of microhematuria and sub-nephrotic proteinuria. Asymptomatic urinary 
abnormalities were seen in 12 (23%) and renal failure without urinary abnormalities occurred in 
23 (44.2%). A small comparison of the clinical features of the present study with that of Yoshida 
et al46 is presented in the following table. 
Clinical feature Present study.  N(%) Yoshida et al46.  N(%) 
Number of patients 52(100%) 31(100%) 
Nephrotic syndrome 8 (13.4%) 17 (54.8%) 
Sub-nephrotic proteinuria 15 (28.8%) 5 (16%) 
Microhematuria with 
proteinuria 
4 (7.6%) 2 (6.4%) 
Renal failure 25 (48%) 7 (22.6%) 
 
HISTOPATHOLOGY: 
Renal biopsy was done in 29 patients who had normal sized kidneys and presented with 
urinary abnormalities or renal failure or both. The remaining 23 patients had reduced kidney size 
with grade III echoes or poor cortico- medullary junction. Hence biopsy was not considered in 
this group of patients. The following discussion pertains to the cohort of patients who underwent 
biopsy.  
The most common pathology noted was mesangial proliferation which was observed in 9 
cases. The proliferation was diffuse in 2 and focal in remaining 7 patients. Focal endocapillary 
proliferation occurred in 5 cases and IgA nephropathy was observed in 3. Membranous 
nephropathy, amyloidosis, minimal change disease and focal segmental glomerulosclerosis were 
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noted in 2 patients each. A comparison of histopathologic findings of the present study and other 
international studies is presented in the following table. 
 
 
 
As far as the biopsy procedure is concerned, it was done after ensuring normal bleeding 
and clotting parameters. The position of the kidney was marked with ultrasound and biopsy was 
done. There were no major complications of the procedure noted. None of the patients developed 
macrohematuria and neither fluid resuscitation nor blood transfusion was required.  
STUDY 
Mes 
PG 
Foc 
EPGN 
IgA
N 
MN 
Amyloid
-osis 
MCD FSGS 
Vascu-
litis 
Others 
Present 
Study 
(n=29) 
9 5 3 2 2 2 2 - 4 
Boers et al16 
(n=132) - 1 - 9 15 - 5 8 120* 
Yoshida et 
al46 (n=31) 2 2 - 16 6 - - - 5 
Helin et al23 
(1986) 
(n=39) 
11 - - 9 16 - - - 3 
Korpela et 
al25 (n=74) 23 - - 13 20 - - - 18 
Nakano et al26 
(n=158) 54 2 31 49 30 - - 1 22 
Helin et al32 
(1995) 
(n=110) 
40 4 - 19 33 3 - - 11 
Mes PG - Mesangial proliferative glomerulopathy; Foc EPGN - Focal endocapillary 
proliferative  glomerulonephritis; IgAN - IgA nephropathy; MN - Membranous 
nephropathy; MCD - Minimal change disease; FSGS - Focal segmental glomerulosclerosis. 
*- 119 cases were found to have arteriosclerosis and reported by author as benign 
nephrosclerosis. 
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MESANGIAL PROLIFERATIVE GLOMERULOPATHY 
This category includes glomeruli with proliferation of mesangial cells which can be focal 
or diffuse. As evident from the table, this is the commonest pathology reported in RA. Though 
the exact pathophysiology behind the development of mesangial proliferation is not clearly 
understood, there is evidence that it could be caused by RA itself and not by drugs. In the study 
by Nakano et al26, the author found that about two-thirds of patients who had mesangial 
proliferation were not on DMARDs at all throughout the course of their illness. Koseki et al47, 
undertook a prospective study in 235 patients to analyze the impact of the disease and drugs on 
proteinuria, hematuria and renal dysfunction. The authors found that drug induced proteinuria 
and renal dysfunction occurred in only 1.5% and 1.7% patients respectively. All of the 9 patients 
in the present study presented with sub-nephrotic proteinuria, while one had renal dysfunction. 
IGA NEPHROPATHY 
IgA nephropathy occurred in 3 patients in the present series. In a Japanese study by Nakano et 
al26, 31 out of 158 patients had mesangial IgA deposits. Since the prevalence of IgA nephropathy 
in Japan is very high, this result should be interpreted with caution, because it may be related to 
the population bias. Korpela et al25 from Finland reported about 8 cases of IgA nephropathy out 
of 56 patients. In our study, all 3 had sub-nephrotic proteinuria and one each had hypertension 
and macrohematuria at presentation. 
FOCAL ENDOCAPILLARY PROLIFERATIVE GLOMERULONEPHRITIS 
There were about 5 cases of focal endocapillary proliferative glomerulonephritis out of 
29 biopsies (17%) in the present study. Ramirez et al15 reported 3 such cases out of 76 patients.  
Helin et al32 and Yoshida et al46 reported 4 out of 110 and 2 out of 31 cases respectively. This 
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condition is quite rare and some authors consider that 50% of these cases were related to 
vasculitis. However our patients never had features of systemic vasculitis and all the 5 patients 
had varying amount of immunoglobulins like IgM, IgG and complement C3 in biopsy specimen. 
This pattern of immunofluorescence is against the usual pauci-immune nature of vasculitis. All 
the patients in this group had a test done for anti-neutrophil cytoplasmic antibodies (ANCA) and 
were found to be negative. One patient presented with acute nephritic syndrome with low C3 and 
normal C4. He had very high titres of rheumatoid factor and biopsy was consistent with focal 
endocapillary proliferative glomerulonephritis. The remaining 4 patients had normal 
complements. All the patients in this group received a short course of steroids for four weeks 
then slowly tapered. Only one patient did not respond and developed a rapid downhill course. 
She had focal proliferative and sclerosing glomerulonephritis with fibro-intimal proliferation of 
blood vessels. Antibodies to cyclic citrullinated peptides (anti-CCP) which is highly specific for 
RA, was strongly positive in her. She reached end stage renal disease within one month of onset 
and soon became dialysis dependent. Perhaps, she is the only patient who reached CKD-5D in 
this study. 
MEMBRANOUS NEPHROPATHY 
When the causes of secondary membranous nephropathy (MN) were considered, one 
would not forget the drugs used in the management of RA. Most of the literature published in the 
eighties and nineties reported a high incidence of MN because of the higher usage of gold and 
penicillamine in these patients.  Nakano et al26 reported 49 cases of MN out of 158 (31%). Helin 
et al32 had 19 out of 110 (17%) and Yoshida et al46 had 16 out of 31(51.6%) of MN. But the 
incidence of MN is coming down due to the application of newer biological agents in the 
management of RA. However the incidence of MN could not be completely related to gold and 
48 
 
penicillamine alone. The two patients who had MN in the present study were not exposed to 
gold, penicillamine or bucillamine. Their anti-nuclear antigen (ANA) was negative and their 
viral and malignancy screen were also negative. There have been various evidences to support 
that MN can occur in the absence of the drugs known to cause them. In the report by Nakano et 
al26, about 9 of 49 cases did not receive any DMARDs. Honkanen et al37, reported 4 cases of MN 
in rheumatoid arthritis. Only one patient received gold therapy 16 years before the biopsy. Other 
3 patients did not receive gold or penicillamine. The pathogenesis of MN is complex and it is 
worth considering that RA itself can predispose to MN and that drugs might accelerate the 
development of this lesion. 
AMYLOIDOSIS 
 Rheumatoid arthritis is the most common cause of amyloidosis in western countries. In 
India, tuberculosis and other chronic infective diseases still contribute significantly to secondary 
amyloidosis. But one should not forget secondary amyloidosis when a RA patient presents with 
massive proteinuria. The most common risk factor for the development of secondary amyloidosis 
is the duration of RA. Amyloidosis is also one of the commonest causes of renal dysfunction in 
RA. There are only 2 cases of amyloidosis in the present study. Helin et al32, reported the highest 
incidence of amyloidosis which occurred in 33 of 110 (30%). Nakano et al26 reported 30 of 158 
cases (19%). Both of the patients who had amyloidosis in the present study had more duration of 
the disease, more severe joint involvement with deformities and both had nephrotic range 
proteinuria. One patient had renal dysfunction and continued to have renal failure on follow up. 
Poor prognostic factors include cardiac involvement and serum creatinine level greater than 2.0 
mg/dL at presentation29. Since there is no effective treatment for secondary amyloidosis, the 
mainstay of management is aggressive treatment of rheumatoid arthritis. 
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MINIMAL CHANGE DISEASE AND FOCAL SEGMENTAL 
GLOMERULOSCLEROSIS 
Helin et al32 reported 3 cases of minimal change nephropathy. Minimal change disease 
(MCD) can occur as a complication of NSAID as well. There were 2 patients with MCD in the 
present study. Both patients were taking NSAID for more than 4 years. It is very difficult to 
ascertain whether the disease itself or NSAIDs played the role in the pathogenesis of MCD. 
There were not much of reports of focal segmental glomerulosclerosis (FSGS). The present study 
includes 2 patients out of 29 with FSGS. Freidman et al48 reported a case of rheumatoid arthritis 
who presented with nephrotic range proteinuria and did not receive any of DMARDs. The renal 
biopsy in this patient showed focal segmental glomerulosclerosis. Adu et al24 studied about 
glomerular lesions in 10 patients and found focal segmental glomerulosclerosis in one patient. 
It is not known whether RA itself causes FSGS or it is the end result of some other glomerular 
disease manifesting as FSGS. The present study and the few case reports highlighted just provide 
an idea that MCD and FSGS can occur in rheumatoid arthritis. 
OTHER MISCELLANEOUS LESIONS 
Tubulo-interstitial disease occurred in two patients. One patient who had acute interstitial 
nephritis had history of consumption of indigenous medicines, the nature of which is not known. 
This patient also consumed NSAIDs before the onset of renal failure. This patient recovered with 
conservative management. Other patient had acute tubular injury (acute tubular necrosis) and did 
not have history suggestive of volume loss. He also recovered with conservative management. 
Nakano et al26 reported 2 cases of tubulo-interstitial nephritis and Helin et al32 had one case of 
acute interstitial nephritis in his case series.  
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 One case of nodular glomerulosclerosis has been identified in 65 year old gentleman in 
the present study who is not a known diabetic. He presented with nephrotic range proteinuria and 
renal dysfunction. Renal biopsy revealed Periodic acid Schiff positive, weak silver positive 
nodular mesangial expansion that was congo red negative and appeared blue on trichrome. His 
glucose tolerance test and HbA1c were well within normal limits. One other patient had 30 year 
history of RA and presented with subnephrotic proteinuria and renal dysfunction. He was not a 
hypertensive. His biopsy showed moderate thickening of blood vessels suggestive of 
arteriosclerosis and ischemic sclerosis of the tuft. In a study by Ramirez et al15, the authors 
analyzed the renal pathology in 76 RA patients against an age and sex matched controls. They 
found marked intimal proliferation of arterioles in RA group (30%) without hypertension. This 
led the authors to conclude that arteriosclerosis can complicate RA even without hypertension 
and it may be the cause of compromised renal function in RA. 
VASCULITIS IN RHEUMATOID ARTHRITIS 
 Vasculitis occurring either as renal limited or with systemic involvement is not 
uncommon in RA. Harper et al40 reported about 10 cases of RA with vasculitis. All of them 
presented with proteinuria, 9 had renal dysfunction and 8 had microscopic hematuria. Renal 
biopsy revealed focal segmental necrotizing glomerulonephritis with extracapillary proliferation 
in all 10 patients. Nine patients were rheumatoid factor positive and had severe joint erosions. 
Five patients had features of systemic vasculitis and 4 of 5 in this group had p- ANCA positivity. 
Qarni et al66 also reported 2 cases of rheumatoid arthritis with rapidly progressive 
glomerulonephritis. Biopsy was consistent with necrotizing glomerulonephritis. Both of these 
patients had p- ANCA in their serum. However, vasculitic involvement has not been noted in the 
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present study. It seems prudent to consider vasculitis in a case of RA, when the patient presents 
with rapidly worsening renal function even in the absence of systemic features of vasculitis.  
IMMUNOFLUORESCENCE PATTERN IN RENAL BIOPSY 
Three patients had dominant or co-dominant IgA deposits warranting the diagnosis of 
IgA nephropathy. Two cases each in amyloidosis and minimal change disease and one case of 
nodular glomerulosclerosis did not have any immunofluorescent (IF) deposits. In the remaining 
cases, the most common finding was IgM with C3, followed by IgG with C3 and IgG or IgM 
alone. Another important feature noted was 18 of 22 cases that had IF deposits were positive for 
C3. Korpela et al25 studied the immunological profile of RA patients and found that IgM, IgA 
and C3 were the most common IF findings. 
CLINICO-PATHOLOGIC CORRELATION 
This study highlights the fact that renal involvement in rheumatoid arthritis can be 
clinically silent, as exemplified by 27 of 52 patients (52%) included in the present study were 
asymptomatic. Of the 27 patients, 12 had asymptomatic urinary abnormalities and remaining 15 
had raised serum creatinine without urinary abnormalities. All 12 patients who had 
asymptomatic urinary abnormalities underwent renal biopsy. The 15 patients who were 
asymptomatic and had raised serum creatinine also had reduced kidney size with increased 
echoes, hence biopsy was not considered in them. The renal pathology in the asymptomatic 
group is presented in the following table. 
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RENAL PATHOLOGY IN THE ASYMPTOMATIC COHORT ( n=12) 
PATHOLOGY NUMBER 
OF CASES
1.Mesangial proliferative glomerulopathy 8 
2.IgA nephropathy 1 
3.Minimal change disease 1 
4.Focal endocapillary proliferative glomerulonephritis  1 
5.Arteriosclerosis with ischemic glomerulosclerosis 1 
 
In the symptomatic group, nephrotic syndrome occurred in amyloidosis, membranous 
nephropathy, focal segmental glomerulosclerosis and minimal change disease. Of the four cases 
of nephritic syndrome, 3 were due to focal endocapillary proliferative glomerulonephritis and 
one was due to IgA nephropathy. Hypertension occurred in 5 patients. Blood vessels were 
thickened in 7 patients including fibro-intimal proliferation in 2 cases. Out of this 7 patients with 
vascular changes, hypertension occurred in only one patient. This is another example of clinico-
pathological discordance proving that rheumatoid arthritis itself can affect blood vessels. 
OUTCOME AND PROGNOSIS OF GLOMERULAR DISEASES 
Among the patients who had glomerular diseases, 6 had complete remission and 7 had 
partial remission during the follow up period. Remaining 14 patients had persistent proteinuria. 
Duration of the disease (p< 0.03) and a high erythrocyte sedimentation rate (ESR) (p<0.0001) 
were statistically significant risk factors in contributing to persistent proteinuria. Serum C-
reactive protein (CRP) was also high in the persistent proteinuria group, but not statistically 
significant. Koseki et al47 performed a prospective study to evaluate renal disease in 235 RA 
patients and found that serum CRP, ESR and age more than 50 years at entry correlated 
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significantly with persistent proteinuria. Patients with minimal change disease and focal 
endocapillary proliferative glomerulonephritis received oral steroids in the form of tablet 
prednisolone at a dose of 1mg/kg for 6 weeks then tapered over another 6 weeks. Other 
glomerular diseases were treated with angiotensin converting enzyme inhibitors and statins. 
Favourable response in the form of complete remission occurred in 3 cases of mesangial 
proliferative glomerulopathy and one each in focal endocapillary proliferative 
glomerulonephritis, minimal change disease and membranous nephropathy. Partial remission 
occurred in 3 cases of focal endocapillary proliferative glomerulonephritis, one case each in IgA 
nephropathy, membranous nephropathy and minimal change disease. Persistent proteinuria were 
seen in 6 cases of mesangial proliferative glomerulopathy, 2 cases of amyloidosis, 2 cases of IgA 
nephropathy and one case each in focal endocapillary proliferative glomerulonephritis, focal 
segmental glomerulosclerosis and nodular glomerulosclerosis. About 6 patients had renal failure 
at entry into study. On follow up, 4 had persistent renal failure with only one progressing to 
dialysis dependent renal failure. The four patients who had hematuria at entry ceased and none 
had hematuria at follow up. 
CHRONIC KIDNEY DISEASE AT PRESENTATION 
This discussion pertains to the cohort who presented with renal failure with reduced 
kidney size and increased echoes precluding renal biopsy. Total number of patients in this group 
was 23 (44.2%). Mean age was 50 + 10.3 years and female : male ratio was 1 : 1. Mean duration 
of rheumatoid arthritis was 11.1 years. About 15 patients did not have any renal symptoms and 
were detected to have renal failure only on screening. About 4 patients had edema legs at 
presentation and 5 had hypertension. Mean serum creatinine and mean estimated Glomerular 
Filtration Rate(eGFR) at entry were 2 mg/dl and 36.5 ml/mt/1.73 m2 respectively. Almost all the 
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patients received NSAIDs until the detection of renal failure, after which it was stopped. The 
dose of methotrexate was reduced according to eGFR. During follow up only 7 of 23 patients 
had a decline in eGFR and progressed to next stage of chronic kidney disease. Rest of the 
patients maintained relatively stable GFR. The mean eGFR at follow up was 31.1 ml/mt/1.73 m2. 
None of the patient in this cohort progressed to end stage renal disease. 
PROGNOSIS  
Most of the available literature confirms a favorable outcome of renal diseases in rheumatoid 
patients unless complicated by amyloidosis or vasculitis related crescentic glomerulonephritis. 
Korpela et al49, followed 23 RA patients with mesangial proliferative glomerulopathy and found 
that renal function remained stable in all patients. Kelly et al50 recalled 21 RA patients who had 
hematuria at a median of 7.7 years and found normal renal function in all of them. In the 
prospective study of 235 patients by Koseki et al47 with an average observation period of 42 
months, found that drug induced proteinuria and renal dysfunction occurred in only 1.5% and 
1.7% patients respectively. NSAIDs caused renal failure only in those who had an additional 
insult like dehydration or those who received diuretic therapy. Also Pederson et al45 noted that 
gold and penicillamine rather than NSAIDs, contributed significantly to microalbuminuria.  
CAUSE OF DEATH IN RHEUMATOID ARTHRITIS 
 Laakso et al9 followed 500 males and 500 females with RA with age and sex matched controls 
for 10 years. During the follow up period, 31 RA patients (against one control) died from 
amyloidosis and 42 RA patients (against one control) died from renal diseases including chronic 
renal insufficiency and renal infections. These findings made the author to conclude that renal 
diseases significantly contribute to mortality in RA patients. This study has been published in 
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1986. With the invention of newer DMARDs and biological agents, renal disease as a contributor 
to mortality has become a rarity. The evidence comes from Institute Of Rheumatology 
Rheumatoid Arthritis (IORRA) cohort study, done in Japan and published by Nakajima et al51 in 
2010. The authors followed up 7926 RA patients with the observation period of 35443 person-
years and reported 289 deaths in the study period. The most common causes of death were 
malignancies (24.2%) and respiratory involvement (24.2%) including pneumonia and interstitial 
lung diseases. Renal failure as a cause of death occurred only in 2 of 289 (0.6%).  
NON-INVASIVE MARKERS OF RENAL INVOLVEMENT 
Overt clinical presentation due to renal involvement in RA is rare and worsening renal function 
is also rare unless complicated by vasculitis or amyloidosis52. The present study and various 
other studies reported emphasize that majority of RA patients harbor asymptomatic renal disease. 
Serum creatinine53 and creatinine clearance54 may not be sensitive indicators of renal dysfunction 
in RA. Hence many researchers worked on specialized tests to identify at risk RA individuals.  
1. Microalbuminuria45 is a simple and sensitive test to detect early subclinical renal 
dysfunction and also drug induced renal damage in RA. 
2. Salli et al55 studied microproteinuria in RA patients using multifractional Cellogel RS 
electrophoresis of urinary proteins and found that 11 of 14 RA patients who tested 
negative for routine proteinuria showed microproteinuria. 
3. Niederstadt et al56, used a highly sensitive immunoluminometric assay to measure 
albumin, immunoglobulin G and α1-microglobulin in 24 hour urines of  RA patients and 
classified into glomerular, tubular and mixed glomerular – tubular proteinuria 
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4. Urinary N-acetyl—glycosaminidase (NAG) is a new marker of tubular function and it is 
abnormally raised in renal diseases56. 
5. GFR, creatinine clearance, 24 hour urinary protein and urine sediment has been used for 
assessing glomerular function. 
6. Tubular function was assessed by urine and serum beta-2 microglobulin, urinary NAG, 
urinary glucose and maximum urinary concentrating capacity. 
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SUMMARY 
 
1. Total number of patients studied was 52, with a female : male ratio of 1.5 : 1. 
2. About 27 (52%) were asymptomatic at entry into study. 
3. About 13.4% presented with nephrotic syndrome, 7.6% with nephritic syndrome, 23% 
with asymptomatic urinary abnormalities, 21.2% with hypertension and 3.8% with acute 
kidney injury. 
4. Chronic kidney disease (CKD) is also common, with 23 of 52 patients (44.2%) presented 
with CKD. 
5. The most common renal pathology noted was mesangio-proliferative glomerulopathy 
followed by focal endocapillary proliferative glomerulonephritis. 
6. Membranous nephropathy, IgA nephropathy, minimal change disease and amyloidosis 
were the other histopathologies obtained in this study. 
7. IgM and C3 was the commonest immunofluorescence pattern observed. 
8. Duration of rheumatoid arthritis and a high ESR correlated significantly with persistent 
proteinuria. 
9. Only one patient in the glomerular disease group progressed to dialysis dependent renal 
failure. 
10. Among those who presented with chronic kidney disease, majority maintained a stable 
GFR during the follow up period with only 7 of 23 progressed to the next CKD stage. 
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CONCLUSION 
 
1. Renal involvement in rheumatoid arthritis can remain asymptomatic. Hence a well 
planned screening is essential to identify renal involvement early. 
2. There can be a wide variety of renal diseases caused either by the disease itself or by the 
drugs used to treat the condition, and very often it may be difficult to differentiate 
between the two. 
3. Renal biopsy remains the ‘gold standard’ procedure in diagnosing the renal pathology 
with certainty. 
4. Mesangio-proliferative glomerulopathy followed by focal endocapillary proliferative 
glomerulonephritis were the commonest glomerular lesions noted in the present study. 
5. Membranous nephropathy is declining, owing to the phasing out of gold and 
pencillamine therapy. It can still occur in the absence of exposure to these drugs. 
6. Chronic kidney disease also occurs with increased frequency in rheumatoid arthritis, with 
majority of patients maintaining a stable GFR.  
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1 42 M 54.5 ‐ 6MON ‐ ‐ ‐ ‐ ‐ N N 150/90 2+ 10‐15 RBC 2.5 60 48 2.4 31 13.6 >256 FOCAL PROLIFERATIVE GN, ACUTE TUBULAR INJURY 0.4 1.2 62 50
2 38 F 52 ‐ 8Y 8 10 y ‐ ‐ N N 120/80 2+ ‐ 1.8 120 32 0.8 78 8.2 72 IgA NEPHROPATHY 2.4 0.9 70 110
3 35 F 56 E,O,H 6MON ‐ ‐ ‐ ‐ ‐ N SWAN NECK DEFORMITY+ 120/80 4+ 20 RBC 1.8 50 40 1 69 12.8 256 FOCAL PROLIFERATIVE GN 0.9 0.9 77 40
4 36 F 49 ‐ 5Y 5 10 ‐ ‐ ‐ N N 90/60 3+ ‐ 2.5 80 35 0.8 75 8.6 96 DIFFUSE MESANGIAL PROLIFERATION 1.8 0.7 86 80
5 50 M 50 ‐ 30Y 30 10 Y HCQ ‐ N BOUT. DEFORMITY+ 130/80 1+ ‐ 1.6 60 86 2.9 22 17.4 144
ISCHEMIC GLOMERULOSCLEROSIS WITH MODERATE TUBULAR ATROPHY & 
MODERATE ARTERIOLOSCLEROSIS 1.8 1.8 35 70
6 58 F 52 E  2Y 2 10 ‐ ‐ ‐ SUB NOD ULNAR DEVIATION HANDS 160/80 4+ ‐ 4.2 60 20 0.8 63 12 48 MEMBRANOUS NEPHROPATHY 0.19 0.7 72 50
7 21 M 55.5 E,O  3Y 1 10 ‐ HCQ ‐ N B/L SMALL JT ARTHRITIS 120/80 3+ 8‐10 epi cell 3.7 90 48 1.2 66 8.6 128 FOCAL SEGMENTAL GLOMERULOSCLEROSIS 2.8 1.2 76 80
8 18 M 52.3 ‐ 1.5Y 1.5 7.5 Y SULFASALA‐ N N 120/80 1+ 2‐4PC 1.3 40 26 1 88 12.5 48 FOCAL PROLIFERATIVE GN 0.8 1 89 40
9 33 F 51.8 E 3Y 3 10 Y ‐ ‐ N SWELLING OF PIP&MCP JOI 120/80 3+ 2‐4 EPI CELLS 3.9 45 30 1 65 8.5 176 MEMBRANOUS NEPHROPATHY 1.8 1.1 59 40
10 62 F 62.6 O 2Y 1 10 ‐ INDIGENO ‐ N N 144/96 TR 6‐8 PC 0.4 50 56 1.5 38 24 72 AIN WITH ACUTE TUBULAR INJURY 0.3 0.9 64 40
11 40 F 57.2 ‐ 6MON ‐ 10 ‐ ‐ SUB NOD SWELLING OF PIP JOINTS 140/90 2+ 4‐6PC 2.1 50 24.4 1 68 15 >256 FOCAL PROLIFERATIVE GN 1.2 0.7 96 30
12 35 M 53.7 ‐ 2Y 2 10 Y ‐ ‐ N N 140/90 2+ 2‐3 EPI CELL 2.3 75 76 1.1 72 8.1 248 MILD MESANGIAL PROLIFERATION 1.4 1.1 71 75
13 49 F 64 E 2Y 2 5 ‐ HCQ ‐ N PIP SWOLLEN & TENDER 100/70 3+ 5‐6 EPI CELL 3.5 40 18 0.8 86 12.5 96 FOCAL SEGMENTAL GLOMERULOSCLEROSIS 1.2 0.9 76 20
14 38 M 67 E,O 15Y 12 10 Y ‐ ‐ SUB NOD ULNAR DEVIATION  HANDS 100/70 3+ 5‐6 PC 5.9 80 48 2.1 45 24 96 AA AMYLOIDOSIS 3.4 2.4 40 80
15 49 F 68.5 ‐ 6Y 2 7.5 ‐ ‐ ‐ N B/L SMALL JT ARTHRITIS 130/76 3+ ‐ 2.6 45 34 1.2 61 8 56 MINIMAL CHANGE DISEASE 1.2 1 74 40
16 23 F 41 E,O 2Y ‐ 10 ‐ HCQ ‐ N B/L SMALL JT ARTHRITIS 120/80 3+ 8‐10 RBC 3.2 100 48 2 28 16.8 >256 FOCAL PROLIFERATIVE & SCLEROSING GN WITH CHRONIC CHANGES  2.1 4.2 13 90
17 25 M 45 E,O 7Y 7 10 Y ‐ ‐ N SWAN NECK DEFORMITY+  &120/80 4+ 2‐3 EPI CELL 6.8 110 24 0.8 90 13.7 240 AA AMYLOIDOSIS 3.6 0.9 80 80
18 44 F 70 H 4Y 4 10 ‐ ‐ ‐ N N 120/70 2+ 20‐25RBC 2.4 30 28 1.2 78 7 64 IgA NEPHROPATHY 0.8 0.9 104 20
19 45 F 56.6 ‐ 8Y 8 7.5 Y HCQ ‐ SUB NOD PIP SWOLLEN & TENDER 130/80 1+ ‐ 1.8 40 35 1.1 68 6 ‐ MILD MESANGIAL PROLIFERATION 0.23 1 75 30
20 38 F 71 ‐ 9Y 9 10 ‐ ‐ ‐ N N 140/90 2+ ‐ 2.1 75 24 1 101 8 40 IgA NEPHROPATHY 1.4 0.9 112 60
21 56 F 59.2 ‐ 12Y 12 5 ‐ HCQ ‐ SUB NOD B/L SMALL JT ARTHRITIS 130/80 2+ 5‐7 EPI CELL 2.2 80 30 1.1 53 8 ‐ MESANGIAL PROLIFERATIVE GN 1.6 0.8 73 80
22 37 F 56.8 E 7Y 7 7.5 Y ‐ ‐ N N 120/80 3+ 2‐5 EPI CELL 2.5 20 26 1 69 7 ‐ FOCAL MESANGIAL PROLIFERATION 0.34 1.1 63 20
23 40 F 64.7 ‐ 6Y 6 7.5 Y HCQ ‐ N SWELLING OF PIP JOINTS 110/70 2+ 2‐4 PC 1.8 28 22 1 76 6 136 MILD MESANGIAL PROLIFERATION 0.16 1.2 64 20
24 34 F 47.8 ‐ 4Y 4 7.5 y HCQ ‐ N PIP SWOLLEN & TENDER 120/70 1+ ‐ 1.7 60 23 0.9 66 18 80 FOCAL MESANGIAL PROLIFERATION 1.4 0.7 85 60
25 52 F 53.9 ‐ 9Y 9 10 ‐ HCQ ‐ N N 130/80 2+ 10‐15 EPI CELL 2.1 70 22 1.1 51 12 56 MESANGIAL PROLIFERATIVE GN 1.8 0.8 70 70
26 48 M 64.8 ‐ 5Y 5 10 y ‐ ‐ N N 120/80 1+ 2‐7 EPI CELL 0.8 55 34 1.8 46 6 80 ACUTE TUBULAR INJURY 0.7 1 83 40
27 38 F 56.6 ‐ 7Y 4 7.5 ‐ HCQ ‐ SUB NOD PIP SWOLLEN & TENDER 110/70 3+ ‐ 2.4 40 24 1.4 49 14 ‐ DIFFUSE MESANGIAL PROLIFERATION 2.6 1.1 62 50
28 48 F 64.4 E 6Y 6 10 ‐ ‐ ‐ N N 120/80 3+ ‐ 3.8 60 38 1 83 12 144 MINIMAL CHANGE DISEASE 0.34 0.9 91 40
29 65 M 54 E 20Y 15 10 Y HCQ ‐ N B/L SMALL JT ARTHRITIS 110/70 3+ ‐ 3.5 55 45 1.6 35 16 152 NODULAR GLOMERULOSCLEROSIS, MODERATE ARTERIOSCLEROSIS 3 2.1 27 40
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30 43 M 64.3 ‐ 8Y 7 10 ‐ HCQ ‐ N N 130/80 TR ‐ 0.29 35 62 2.8 31 5.6 ‐ ‐ 2.5 35 50
31 38 M 56.7 ‐ 7Y 6 10 Y HCQ ‐ N B/L SMALL JT ARTHRITIS 120/80 1+ ‐ 0.7 25 48 2.2 37 17.2 80 ‐ 2.4 33 30
32 56 M 63.9 E,O 16Y 14 10 ‐ ‐ N B/L SMALL JT ARTHRITIS 130/80 ‐ OCC PUS CELL 0.06 40 66 3.2 23 6.9 72 ‐ 4.2 18 60
33 56 M 67 ‐ 13Y 9 10 Y ‐ HT N BOUT. DEFORMITY+  140/90 TR 10‐16 PC 0.7 45 54 2.2 36 22 32 ‐ 3.5 22 70
34 48 F 56.8 ‐ 8Y 6 10 Y HCQ ‐ N N 110/80 NIL ‐ 0.8 40 56 1.9 32 11 ‐ ‐ 2.1 29 85
35 55 F 54.3 ‐ 9Y 5 10 ‐ ‐ ‐ N SWELLING B/L MCP&PIP 110/80 NIL ‐ 0.2 65 49 2.1 26 8.4 72 ‐ 2.4 23 45
36 50 F 59 E 14Y 14 10 Y ‐ ‐ N N 130/80 NIL ‐ 0.4 65 46 1.6 39 5.4 48 ‐ 1.9 33 50
37 55 F 61 ‐ 10Y 6 10 Y HCQ ‐ SUB NOD  B/L SMALL JT ARTHRITIS 130/80 NIL ‐ 0.08 55 74 2.6 24 16.2 88 ‐ 2.8 22 30
38 52 F 55.2 ‐ 10Y 7 5 ‐ ‐ ‐ N N 110/80 NIL 10‐15 EPI CELL 0.06 80 30 1.5 38 5.7 72 ‐ 1.7 34 40
39 62 M 58.1 ‐ 18Y 14 7.5 Y ‐ ‐ N N 120/80 NIL 1‐3 PC 0.32 60 46 1.6 39 7 96 ‐ 2.5 25 65
40 62 M 67.5 ‐ 22Y 19 7.5 Y HCQ HT N B/L SMALL JT ARTHRITIS 140/90 NIL ‐ 0.13 45 48 1.8 41 4 64 ‐ 1.9 38 70
41 25 F 53 ‐ 2Y 1 5 ‐ ‐ ‐ N B/L SMALL JT ARTHRITIS 120/80 NIL 1‐2 EPI CELL 0.2 60 36 1.7 42 8 32 ‐ 1.6 45 30
42 60 M 58.9 ‐ 14Y 12 5 y ‐ HT N N 140/90 NIL ‐ 0.2 60 34 1.6 41 6 ‐ ‐ 1.9 34 40
43 27 M 64 ‐ 4Y 2 5 ‐ ‐ ‐ SUB NOD PIP SWOLLEN & TENDER 120/80 NIL ‐ 0.16 36 28 1.7 59 6 64 ‐ 1.8 56 35
44 67 M 62.1 E 14Y 11 10 ‐ HCQ ‐ N N 120/80 1+ 1‐2 EPI CELL 0.43 40 86 3.7 17 6 ‐ ‐ 3.5 18 55
45 45 M 66.5 ‐ 11Y 10 10 Y ‐ HT N B/LHALLUX VALGUS 140/90 1+ 2‐3 PC 0.8 80 38 1.4 63 9 96 ‐ 2 44 40
46 54 F 62.6 ‐ 13y 12 10 ‐ ‐ ‐ N N 120/80 ‐ ‐ 0.4 30 54 2.4 31 12 120 ‐ 2.7 28 30
47 45 F 57.3 ‐ 9Y 7 10 Y ‐ ‐ N N 110/70 TR 3‐4PC 0.24 45 45 1.7 44 8 72 ‐ 2 38 30
48 49 F 48.3 ‐ 11y 9 10 ‐ ‐ ‐ N N 120/80 TR ‐ 0.18 45 43 2.4 22 6 ‐ ‐ 2.6 20 20
49 54 F 57.5 ‐ 16Y 12 10 ‐ HCQ ‐ SUB NOD B/L SMALL JT ARTHRITIS 130/80 1+ 1‐3 PC 0.5 35 38 1.9 36 12 120 ‐ 2.4 29 40
50 44 M 63.4 ‐ 8Y 5 10 ‐ ‐ ‐ N N 120/80 1+ ‐ 0.7 30 29 1.6 53 8 ‐ ‐ 1.9 44 65
51 58 M 58.4 E 11Y 11 10 ‐ ‐ HT N N 140/90 1+ ‐ 0.32 35 43 2.1 32 8 72 ‐ 3.8 18 45
52 47 F 60.2 ‐ 7Y 7 7.5 ‐ ‐ ‐ N B/L SMALL JT ARTHRITIS 130/80 TR ‐ 0.16 30 44 2.2 35 6 96 ‐ 2.6 30 30
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INTRODUCTION Rheumatoid arthritis (RA) is a chronic crippling disease that affects various organ
systems including the kidney. RA is the second most common rheumatologic problem next only to
SLE. Renal involvement in RA can be either due to the disease per se or due to the drugs used to
treat the condition. RA can affect all the components of the kidney including the glomerulus, tubules
and interstitium and the blood vessels. Most of the patients will be taking non-steroidal anti-
inflammatory drugs, the potential renal toxicity of which is well known. Gold and penicillamine used in
the management of RA has been very well known for their nephrotoxic potential by causing
secondary membranous...
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NAME:                       AGE:                              SEX:                     
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Edema                                                         Early morning stiffness                                  
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Other nephrotoxic drugs: 
Indigenous medicines: 
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GENERAL EXAMINATION: 
Skin                                                                          Pallor   HT: 
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